Verastem to Present at the 29th Annual J.P. Morgan Healthcare Conference

BOSTON--(BUSINESS WIRE)-- Verastem, Inc., a biopharmaceutical company focused on discovering and developing drugs to treat cancer by targeting cancer stem cells, announced today that it will be presenting at the 29th Annual J.P. Morgan Healthcare Conference at 12:30 pm PST (3:30 pm EST) on Thursday, January 13th, 2011. The presentation will focus on the Company's strategy for translating breakthrough discoveries in cancer stem cell research into new medicines for the treatment of major cancers.

About Verastem, Inc.

Verastem, Inc. is a private biopharmaceutical company focused on discovering and developing novel drugs that selectively target cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. Verastem is translating breakthrough discoveries in cancer stem cell research into new medicines for the treatment of major cancers such as breast cancer.

Verastem was founded by Rich Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric Lander, Robert Weinberg and Christoph Westphal.

Verastem is backed by Bessemer Venture Partners, Cardinal Partners, Longwood Founders Fund, and MPM Capital.



CONTACT:

Weber Shandwick
Lacy Roosevelt, 617-520-7052
[email protected]

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Oncology  Pharmaceutical  Research  Science  General Health

MEDIA:

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.